ALF funds for 2020 can be used next year too

The coronavirus pandemic has affected the ability of the ALF regions to conduct clinical research. The Government is now making an addition to the ALF agreement, so that the regions can use their 2020 funds also during 2021.

The regions that receive ALF funding to conduct clinical research, educate physicians, and develop health and medical care have warned that hundreds of millions of kronor in research funding cannot be used during 2020. According to the current ALF agreement, unused funds must be repaid. The Government has decided to enter into an additional agreement that makes it possible for the regions to use this year’s ALF funding also during 2021.

Read the press release on the Government’s website (in Swedish) External link.

Evaluation of research quality is postponed

The pandemic is also creating consequences for the evaluation of clinical research quality in the ALF regions. Because of the great strain placed on health and medical care, the Swedish Research Council has postponed the evaluation until 2022.

About the evaluation of research quality in the ALF regions




  1. Just over 75 per cent of clinical studies registered after one year

    As from 2022, all clinical studies funded by the Swedish Research Council shall be registered in a public database. A recent follow-up shows that the majority of the clinical studies awarded funding in 2022 have been registered.

  2. What are the conditions for clinical research in Sweden?

    Clinical research is necessary for developing and improving healthcare in Sweden. The Swedish Research Council has now found out what researchers and doctoral students think about the conditions for conducting clinical research.

  3. Nominate researchers for the Athena Prize 2023

    The Athena Prize is awarded for research and innovations that have been created in collaboration between health and medical care, academia and the business sector. You can take part and influence who gets the prize this year. The deadline for nominat...

To top